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The special branches ofl.iver and intestinal transplantation developed outside of ASTS, and became well represented at our meetings only after their maturation 
was far along. Most of the key advances first appeared in conventional clinical 
journals, including those devoted to surgery. The evolution of the major steps can be 
most easily traced in the issues of Transplantationpro¢eedtngs that contain b.iennial 
reports from the Transplantation Society meetings and.off;-year conterencesendorsed 
by the parent organization. These developments will be used as background (but not 
annotated) in the following account. on· which ASTS program presentations wiltbe 
superimposed and systematically cited. For each. notations are includedJ.boutASTS 
manuscripts. including those not published in the. official journal of the society-
Surgery in 1975 and 1976. Transplantation thereafter. 
Successful clinical transplantation of any whole organ rests on 5 specitic laborato-
ry-based struts: surgical technique. preservation technology, tissue matching. im-
munosuppression. and (least appreciated) incidental induction of variable degrees of 
Janor-speclfic nonreactivitv. without which none of our patients could be rehabilitat-
~d tor long. Liver and intestinal transplantation contributed to all 5 Lategories. but 
only the tim 2 have been prominent themes in the published ASTS proceedings. 
However. because of their generic importance to all of transplantation. the last j top-
ics (tissue matching. immunosuppression. and tolerance) will be discussed separately. 
,IS intluenced by the liver and intestine. in the third section ~ntitled TmllSpitllltclClO1I 
I mmww/ogy, 
Liver replacement was lullv Jc.:vdoped c.:xperimc.:mallv bv 1'158 at Harvard t>.1c.:dical 
(:oll~ge Jnd ind~pendenrlv at Northwestern L'niwrsitv. (hicago. The.: live.:r was Ihe.: 
lirst nonrenal vital organ 10 b~ transplanted dinicallv ( t 'io]) ill attempts I hat Wt'r~ 
(fawned With long surVival in 1'107. Those involved wcrel.argdv from the ranks or" the 
kidne.:v tr:msplant surgeuns who ~llhcr bdungt.'J to ASTS or wt.'rc wdl-known 10 ItS 
-----------~~-----
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membership. Yet only 4 experimental (1-4) and 6 clinical papers (4-10) covered liver 
transplantation during the period of its most explosive development (1975-1984). 
Abstracts about the liver either were not being submitted or were not being selected, 
or perhaps both factors contributed to the paucity. All the while, a pool of chronically 
surviving recipients was enlarging. By 1989, when Scandebury (Colorado-Pittsburgh) 
reported the successful pregnancy of 17 women (16 of whom were 2 to 18 years post-
transplant), the oldest child was already 13 years old (11). 
or those 4 early experimental studies, 3 were of hepatic (or hepatocyte) trans--
plantation to ectopic sites. In 1977, Hong, working with the late Samuel Kountz 
(Brooklyn), reported a new technique for auxiliary liver transplantation in dogs (1). 
After Kountz's death. Moritz and Jarrell (12) from Philadelphia (Jefferson. 1989) 
described the successful treatment of fulminant hepatic failure with an allograft 
placed in the right paravertebral gutter; the auxiliary liver was allowed to reject and 
involute after the native liver had recovered. Hepatocyte transplantation intraspleni-
cally and intraperitoneally, respectively, were introduced to ASTS in 1979 by Mito 
(Asahikawa, Japan) (3) and Makowka (Toronto. 1980) (4), using rat models that have 
subsequently been widely used for a variety of experimental purposes. Makowka 
showed that the mortality of experimentally induced fulminant failure could be 
reduced equally. with allogeneic or xenogeneic (rabbit and pig) hepatocytes. 
Virtually aiL other presentations have. invol:ved liver. replacement (orthotopic 
transplantation), w.itha·heavy-.~Iin,iCalI!1'ItJ'hasis on. technical problems. The first of 
these.( 5) described theinciden~~~:'etl~IOgy,'and prevention ( or secondary correction)· 
of biliary tract complicatio·ns(Golor3.:(iofJ.9.76). Since then. biliary reconstruction. 
once the Achilles heerofliver·transpla,I1~fion~ has beenre.visited at ASTS 4 times: by 
Lerut(Pittsburgh. 1986) (L3l • .sari91e~,;-Urd¥pal (Mayo Clinic. 1991) (14), Hefron in 
connection with reduced~sizeJiveti(Uhi\'ersityofChicago, 1991) (L5). and.Sankary 
(16), who described a modlfied oiiiary reconstructive technique (Rush-Presbyterian. 
Chicago, 1993), 
The Achilles heel designation passed in 1985 to allograft revascularization. 
Andreas Tzakis ( Pittsburgh) documented the frequency of hepatic artery thrombosis. 
which had a predilection for infants and small children ( 171. He also accurately delin-
eated the syndromes that could result from dearterialization. including silent occlu-
sion in about a third of cases. Langnas (Nebraska) reported emergency revasculariza-
tion of the occluded artery in 1990 ( 18). Stevens (Universitv of Chicago. 1991) noted 
no greater incidence in reduced-size pediatric liYers than in whole ones (19). Portal 
yein complications. which occur much less frequently, were described bv Reed (Wis-
consin. 1991) (20 l. 
Until the end of 1982. only 1 or .3 liver transplant teams were able at a technical 
level to obtain results resembling today·s. Training the next generation was facilitated 
in 1983 bv (he introduction in Pittsburgh or a veno-venous lwpass (echnique. It 
Jllowed decompression of the obstructed portal and vena caval beds while the dis-
eased liver was removed and the m:w one sutured in place. :\Ithou~h liver replacement 
(auld be performed bv skillful surgeons without a veno-wnous bvrass. JS cmphasized 
bv Wall (London. Untano. 1 ':IH6) (211. most new teams adopted (he bypass tcchntque 
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for their first cases after Shaw's report at the American Surgical Association in 1984. 
Convinced of its value, they have used it in the succeeding years, either routinely or as 
indicated by test occlusion of great veins. 
Bleeding caused by fibrinolysis can occur with or without venous bypass. 
Pohorecki (Nebraska. 1993) reponed that such bleeding could be ameliorated by 
epsilon amino caproic acid (EACA) (22), a drug that had been used for the same pur-
pose in the early 19605 but abandoned because of dotting complications. A discrimi-
nating revisit to the past also was reponed by McAlister (London, Ontario, 1992), 
who described right diaphragmatic paralysis in several pediatric liver recipients (23). 
This previously had been attributed to crushing of the right phrenic nerve with the 
suprahepatic venal caval damp at the diaphragm, a conclusion validated by McAlister 
with meticulous scientific rigor. 
Cataloguing quality oflife issues and nontechnical complications after liver trans-
plantation largely recapitulated an analogous literature 2 decades earlier in renal 
transplantation. An exception, because it concerned a new disease. was a report by 
Tzakis (Pittsburgh, 1989) on the postoperative course ()f25,patients (15 liver recipi-
ents) with HIV (24). By systematically screening stored and current blood samples, it 
was shown that 11 of these recipients hadthediseasepr~transplant; the other 14 were 
infected by blood products or allografts, in thecour~e()f p~rioperative tre:mn,ent 
before the availability of detection methods; Other vir3.l irifection studies (25-28) have 
been of cytomegalovirus and its prophylaxis (Stratta. Nebraska;. Freise, San Francisco, 
1990): Epstein Barr (Langnas, 1992); andhepatitisC(Mateo •. Pittsburgh, 1993). Bac-
terial infections in OKT3-treated liver recipients were reported by Wall (London, 
Ontario, 1990) (29). Koep (Colorado, 1978) noted a high incidence of lethal sepsis 
from colon perforation (7). 
Hepatic preservation first appeared on the ASTS program in 1977 with a report 
by Benichou (Colorado) of successful canine liver storage for up to 18 hours using 
Collins solution. This technique was repeatedlv used for removal of human livers in 
Los Angeles and their transplantation in Denver (2). These and independent achieve-
ments bv William Wall and Rov Caine at Cambridge using a plasma-like preservation 
tluid overthrew the logistic tvrannv of donor-recipient proximitv, but the "safe" time 
limit still was only 6 or 8 hours. This was extended 2- or 3-told with the announce-
ment of the Universitv ot Wisconsin I UW) solution by Belzer and his associates at a 
meeting in Pittsburgh in September 1987. Their claims tor UW were promptly con-
tirmed bv Todo (Pittsburgh) and then widely bv others. This advance was retlected 
belatedlv in ASTS reports in 1989 (Olthotf. UCLA: Str:l.tta. Nebraska) (30.311. 
At the 11)89 ASTS meeting. Pienaar ( Wisconsin) described 72-hour pump preser-
vation 01 the ex vivo dog liver using an asanguinous perfusate (32). This was the tirst 
l1ew and effective continuous perfusion technique since the experimental and clinical 
use, bv the late Larrv Brettschneider \ Colorado J. uf a cumbersome blood-enrtched 
wstem \ which was housed in a hvperb::uic oxygen chamber and had permitted 4/{-
hour preservation lit CJOIne livers I. III (1)88 B.lUmgartner \ fohns Hopkins I h,ld 
Jescnbed continuous [lltJi bodv rcrtusion wllh hvpothermlC c.udiopulmonan· 
hvpass dUring multiple-organ procurement (331 • .l It:chniqut: that had been used dill-
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ically in Colorado for liver and kidney procurement from non-heart-beating cadavers 
in the 1960s before the acceptance of brain death. Although a good quality of thoracic 
and abdominal organs was described. resistance to the complex procedure by person-
nel at outlying hospitals has limited its subsequent application. 
Reduced-size liver transplantation has been a frequent recent clinical topic. This 
procedure was popularized in the early 1980s by Henri Bismuth of Paris (with Didier 
Houssin) and the Hannover team ofRudi Pichlymar (indudingChristophBroelsch). 
Between 1987 and 1992. Broelsch's group (then at the University of Chicago) provid-
ed 5 ASTS presentations (15, 19. 34-36), 2 of which were delivered by Jean Emond. 
These described a progression from the use of reduced-size cadaver liver fragments, to 
the so-called "liver split procedure" in which the allograft was divided and shared by 2 
recipients, and finally to the application of the same_principles to transplantation of 
the left lateral segment or left lobe from living donor adults to children. Both Emond 
(35) and Langnas (Nebraska. 1991) (37) reported disappointing results when 2 recip-
ients were given fragments from a divided liver. 
The indications forliver transplantation received little attention at ASTS meetings 
until the late 1980s. The only exception was a description by Charles Putnam (6) of 
liver replacement for alpha-I-antitrypsin deficiency (Colorado, 1976) -an early 
entry, though not the first, on die list of c~rrectable inborn errors that has grown since 
then to nearly 3 dozen. However, with the shortage of organs that had developed by 
the late 1980s, candidacy began' to be discussed with overtones of organ userestric-
tion. Potential relative~or absolute contraindications to liver transplantation formally 
considered at ASTS (and usually rejected by the'speaker) include old age (Stieber, 
Pittsburgh, 1990) (38), B virus hepatitis:{Boston intracity group.> presented by Eason, 
1993) (39), and hepatic malignancies (Boston-group by Haug, 1991) (40). 
At about the same time, reports emerged on the management of waiting lists, 
questions about who shouldbe allowed on them. and the intluence of disease severity 
on outcome (Gordon. Pittsburgh, 1990) (41l. Criticisms about the candidacy of alco-
holic recipients were largelv defused bv Turcotte (Michigan. 1993) (42), who con-
tirmed previous observ:uions of a low rate of alcohol recidivism in carefully screened 
Jbstaining patients. To meet the growing demand nourished by a shrinking list of 
(ontraindications. Wall (London. Ontario. 1989) (43) showed that many older donors 
(Quid provide satistactory livers. Rosenlof (University of Virginia) described the use of 
the monoethviglycinexidide (MEGX) test to distinguhh good from bad donors (441. 
;\t tirst subtly in 1990 and then with unmistakable darity. the topic shifted to the 
waste of organs bv their "inappropriate" lise to treat very ill reCIpients. However. it has 
,l!wavs neen evident that what constitutes hopelessness in one (t:ntcr mal,' be entirelv 
routine (Jse matenal in more experienced or skillful hands. The argument on this 
uneven plavlng tield has been that high-risk rccipients would h'lYe predictably poorer 
posur::mspbnr survival than wdl ones. Preccding this trend. the lirst ,mempt [() 
<.:4uate scventv 01 illness I and urgency of need) with outcome was made bv Bvers 
Shaw I fJittsburi!h. 1 YH5) with .l formula (45) rhJt has ~lllce bcen n:vlseu ,1I1d widell,' 
lIseo. In all ,It[empt to qUJntlt:ltc the nct!d for an organ and the pa(c of dcterIoration 
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while waiting, Shiffman (Virginia, 1992) proposed sequential pretransplant tests of 
lidocaine metabolism (MEGX) (46). 
Concerns uver the complicated interface between urgency of need, the shortage of 
organs, and their utilitarian use have spilled over to retransplantation. Retransplanta-
tion was first mentioned at the 1983 ASTS meeting by Shaw (Pittsburgh) (8) who 
summarized 21 such attempts in Colorado before 1980, and conuasted the bleak ear-
lier outlook with the better results in Pittsburgh after the advent ofcyclosporine. Pow-
elson of the Boston consortium (47) confirmed that many patients whose grafts failed 
either early or late could be saved, but not with as high a success rate as after primary 
transplantation (1992). As new teams entered the field, their members were inclined 
to deplore the inefficient use of organs for retransplantation until confronted with 
this necessity for their own patients. The propriety of retransplantation. even for 
patients with B virus hepatitis, was defended from the combined experience of the 
Baylor (Dallas) and Mt. Sinai (New York) teams (Crippin. 1993) (48). as long as the 
loss of the primary graft was not from recurrent hepatitis. Otherwise, accelerated 
hepatitis doomed the subsequent graft. as reported earlier by Todo (Pittsburgh, in 
Hepatology, 1991). 
Throughout this recent period, awareness grew that even some of the lowesuisk 
(so-called "boutique") recipients of livers from ideai,donorscol,lldexperience imme-
diate graft failure after an ostensibly perfect operation. The: syndrome was called pri-
mary nonfunction (PNF). Most centershavereported;theneedJorregraftingin the 
first month after primary transplantation at a rateof5%.to.1O%, includinscases with 
no technical imperfections at the first operation~ Excluding this and other identifiable 
causes, the remaining examples of PNF have been mostcommonIy in patients who 
had negative lymphocytotoxic crossmatcheswith,theirdonors. 
However. Knectle's important Upjohn Award presentation (Duke) showed in 
1986 that PNF caused by a slower liver version of the hyperacute rejection seen with 
the kidney and heart could be produced experimentally in presensitized rats (49). 
Gubernatis of Hannover reported similar results in subhuman primates at the Trans-
plantation Society meeting In Helsinki ( 1986); the same thing was described in sensi-
tized pigs bv ~terion (Michigan) at the 1989 ASTS meeting (50 l. Cullectivelv. the ani-
mal studies established that a subgroup of candidates at increased risk of PN F should 
be identitiable with conventional serologic crossmatching. 
. However. a signiticant adverse effect of antigratt cytotoxic antibodies on gratt or 
patient life survival could not be tound by Gordon (Pittsburgh) as late as 1988 (51 ) . 
• md was not clearly established until a report from the same institution at the Trans-
plantauon Society in 1990 and an ASTS presentation bv Takava and Bronsther (52) in 
1991. ~ lost human livers were able to survive the insult. but it was dear that the resIs-
tance of the liver to antibodv relection. wmpared with other or~ans. was onlv relative . 
. \t the succeeding ASTS meetings (I ';192 Jnd ! ';1';13 I. TJkava and 13ronsther 1 Pitts-
bur~h) reported that perioper:mve Intravenous PGEl---..:ombincti with high intiuc-
tion Joses or prednisone-f'racticallv eliminated PNF. with or without .1 posluve 
-:rossmatch 133. 54!. Jnd had the atiJitionai benefit of reducin~ fl(SOh llephro(Oxlcic\'. 
l'his IInportant tindin~ hJti (onslticrable practlc;ll sigmticancc because most liver 
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transplants are performed before the crossmatch results are known. These 2 reports, 
along with an earlier one at the American Society of Transplant Physicians by Levy's 
University of Toronto team, have strongly influenced care of liver recipients. The late 
sequelae of an aborted antibody reaction have not been well delineated, but Batts (55) 
has suggested serious intrahepatic bile duct damage (Mayo Clinic, 1987). 
In a potentially related experimental study, Murase (Pittsburgh, 1992) confirmed 
with xenograft hamster-to-rat models that the liver was less vulnerable than thehean 
to xenospecific antibodies. The damage to both organs could be ameliorated by com-
bining cyclophosphamide. brequinar, RS 61443, methotrexate, and other antimetabo-
lite drugs with FK506 (56). Hyperacute rejection of xenografts. like that ofaUograits. 
has eluded full understanding and control since it was described 30 years ago in ABO-
mismatched kidney recipients (Denver) and in recipients with positive lymphocytox-
ic crossmatches ·(Los Angeles-Denver). Both allografts and xenografts are destroyed 
by a complement activation syndrome that frequently is triggered by antibodies (elas,. 
sical pathway) but may be antibody-independent (alternative pathway). The prospect 
of understanding this formidable barrier was enhanced by Valdivia's hamster-to-rat 
liver xenotransplantexperirn.ents (Pi~burgh, 1993), which showed homologous 
restriction of the predominantly hamster:complement found in the long,.survivingrat 
recipients (57). The possibility>QfMHGrestriction of complement within species 
could help explain why theliverall~graft (which like the xenograft transforms-the 
recipient complement' environment to its own phenotype) is so relatively resistant to 
hyperacute rejection. 
The often unpredictablc"eariy and: late course of the human liver recipient~and 
the morbid or lethal consequences offailing to react in time with therapeutic adjust-
ments to graft dysfunction, have generated numerous attempts to avoid the use of 
faulty organs and toq.uicklydetermine-theprognosis when they begin to tail. Predic-
tion of PNF by the presence of fatty infiltration in donor liver biopsies was reported 
elsewhere in 1989 by Todo (Pittsburgh) and at the ASTS meeting by 0' Alessandro 
(University of Wisconsin) in 1990 (58) . The adverse etfect of this and other prognos-
tic factors was studied with multivariate analvsis in 11)92 by the; Wisconsin group 
( Ploeg, 1992) (59) . The perioperative monitoring of anaerobic metabolic indices pio-
neered by Aldrete (Colorado) and Kang (Pittsburgh) tirst appeared on the ASTS pro-
gram in 1986 (Stock. Minnesota) (60), Asonuma (Pittsburgh and Kvoto. 1990) (() 1 ) 
and Takaya (Pittsburgh. 1993) (54) showed the early diagnosis of this condition by 
serial measurements of the arterial ketone bodv ratio. 
In vitro monitoring of cellular immunitv further along in convalescence was 
reported by Fung in 1985 (Pittsburgh) (62). The following year. :-'Iohanakumar 
l Washington) described the postoperative waxing and waning of antidonor HL\ 
antibodies (63), Serial determmations of circulating inrerleukin II (IL2) or I L2 recep-
tor levels bv Perkins (Mavo Clinic. 1988) (64) and Simpson (Harvard-Northeastern. 
19901 (65) Jnd of intragrart CYtokine gene expression (c.:specially [L5) by Martinez 
( University at California. San francisco. 1991) (66) have not heen wldelv used. Foster 
(07) (Rush-Presbvterian. 19R8) reported that c.:osinophilia postoperatlvc{v signalc:c.i 
rejection with a bad prognosis. 
...... ' 
'--------------
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As with kidney transplantation. allograft function tests combined with histo-
pathologic studies have provided the most reliable guidelines to monitor liver grafts 
and evaluate causes of poor performance. This was strongly emphasized by Williams 
in 1984 of Rush-Presbyterian (Chicago) (10), who obtained biopsies as often as daily 
through an opening left in the wound. Although this "window" technique has not 
supplanted the closed needle biopsy, these pioneer studies demonstrated the frequen-
cy with which rejection would have been treated with increased immunosuppression 
without the benefit of biopsy, when in fact the diagnosis was something else. Further 
experience of the same Chicago group was described by Sankary in 1988 (68). Infor-
mation of research interest also has emerged frOm the serial biopsies, exemplified by 
the studies by So (Minnesota, 1986) of Class I antigen induction of bile. duct cells and 
hepatocytes at the time of rejection (69). Perkins (Mayo Clinic) also described sophis-
ticated immunohistolabeling of the specimens to stratify infiltrating T lymphocyte 
subsets (70). 
Intestine 
Only 11 papers on this subject have been on ASTS programs over a 19-year span. none 
before 1984. The historical roots of bowel transplantation can be traced back to the 
beginning of the century. But the modem era was signaled, by the canine experiments 
reported by Richard Lillehei of Minnesota at the 1959 American Surgical Association 
meeting. The following year, at the Surgical Forum of the American College of Sur-
geons. multivisceral transplantation was describedin dogs;(Northwestern. Chicago). 
This was the forerunner of a nearly identical clinIcal procedure. after which a child 
survived> 6 months (Pittsburgh. 1987). A variant operation of composite liver-
intestinal transplantation permitted genuine rehabilitatiQn of a patient in Landon. 
Ontario (Grant. 1988). These 2 cases were the tirst.eXlllpplesofprolonged human 
intestinal allograft function and reignited interest in thesub;ect. In 1988. the German 
Delph (Kiel) reported long-term survival of a recipient of a segmental small bowel 
graft from a related donor. In 1989. Goulet of Paris transplanted a near-total cadaver 
smail bowel into a child who is still alive nearly 5 wars later. Thus. the intestine \V.\S no 
longer a "forbidden organ" bv the late I Y80s. 
The expenmental basis in large animals tor these trials with cydosporine-based 
immunosuppression had been laid during I YM 1 bv canine experiments in Toronto 
.lOd Pittsburgh. but survival tor 1 or 1 years was an unusual accomplishment. Better 
results in rodents were obtained in several laboratories during the next J years. At the 
1984 ASTS meeting. Raiu. Cavirli. and Didlake (711 reported the greatly increased 
dficacv of cvclosporine relative to azathioprine in rat Ll:wis recipients ot ALl 
intestines. In 1987 Grant (London. Ontario) presented a landmark study in pigs at the 
;\STS meeting t 72l. In Gram's laboratories. extraordinarv efforts were made to pro-
\'ide unmterrupted intravenous cvclosporine. Jnd most animals survived tor ;- 100 
Javs. The irregular and unpredictable absorption ut cvclosporine bv the intestinal 
.dlo~ran made the intravenous trcatmcnt necessary. Two years later. Xia and Kirkman 
'Harvard-llrighamJ reported disqUIeting news: in r:HS. lluestinal allo~ralts produced 
----"----,--
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secretory 19A normally, but 19A response to immunization with cholera toxin (73) 
was deficient or absent. 
When fK506 became available. Murase (Pittsburgh) established. by 1989, its 
superior efficacy relative to cyclosporine in preventing rejection of both isolated 
intestinal and multivisceral allografts. Absorption of this new oral drug was less influ-
enced by intestinal dysfunction, compared with cyclosporine. The stage was set for 
clinical trials. At the 1991 ASTS meeting. Tado and Tzakis (Pittsburgh) presented 5 
examples oflong-surviving human recipients: 4 with liver intestinal grafts, and 1 with 
an isolated complete small bowel graft (74). Todo and Tzakis returned to the 1993 
ASTS meeting with a series of 15· isolated small bowel cases; 12 of the recipients had 
survived for 1.5 to 19 months (75). However. the emphasis on both occasions was less 
on the successes than on the difficulty of clinical care and the need for an improved 
strategy, including better ways of monitoring rejection. A sophisticated means of 
monitoring was suggested by Morrissey (Yale. 1993), who showed a decline of small 
bowel fatty acid binding protein with rejection, as well as the potenthd reversibility of 
this change (i6)' However. as with the other whole organs. monitoring at a practical 
level has been largely dependent so far on serial biopsies. 
The next large advance. presumably will be therapeutic. with better control of 
rejection and the induction· of a drug-free tolerant state without the penalty of 
GVHD. As an effort in this direction •. 4 rat studies were presented at ASTS meetings 
over a 6-year period from Monaco's Harvard-Northeastern laboratory. The first, in 
1984 by Pomposselli:(77), wasa:detailedstudy ofGVHO (originally described.in .1973 
by Monchik and Russell) after intestinal transplantation in the parent-to-offspring f, 
hybrid model. In 1987, Shaffer won the Upjohn Award (78) and in 1990. theOrtho 
Award (i9) for demonstrating avoidance of GVHD by lymphoid depletion of the 
donor pretransplant. or the recipient posttr:msplant. with polyc1onal or monoclonal 
ALS. Diflo showed in 1988 that GVHO could be chronically tolerated in fully allo-
geneic rat intestinal recipients if cyclosporine therapy was maintained chronicallv 
(80) . 
L'sing a different approach. ~layoral (Minnesota) reported'in 1988 that the F 
hybrid rat recipient could be protected from GVHD bv prior conditioning with smali 
doses of parental lymphoid cells or short segments of parental intestine (81 l.The clin-
ical implications of the foregoing body of work. with its emphasis on graft lymphoid 
depletion or host preconditioning. is now oeing reassessed in light of discoveries 
about cell migration and its relation to tolerance. 
Transp/(lIltClCIOII Immllllology 
Immunosuppression. When cvclosporine was introduced and its use wuh prednisone 
~tandardized in 19i8-19HO. the most dram;:ttic impact was 1111 liver .lOci other 
-:xtr;:trenal transplants. This was widelv known by the end oIl ,;)HO and was a prime. ,I 
flot the prtnClpal. rcason [or the dru~'s r~lpld approval by thc rood and Drug Admlll-
istr;:ttlon , FDA I in Nowmber I':IH3. For the lirst (IInc. the nonrenal or~Jns {liver anti 
hc;:tnJ 11.ld shan:d prtmarv responSIbility WI! h the kidnc\' III 1111 l11UIH)suppressive dru~ 
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development. However, the subject of cyclosporine in the context ofliver transplanta-
tion was not brought to an ASTS meeting until 1983 (9) in a clinical study of dose 
weaning over the first 12 months. Iwatsuki (Pittsburgh) and Shaw (Pittsburgh) 
reported that cyclosporine upgnided the prognosis after liver retransplantation (8). 
Similarly, Cosimi's report (82) on the use of OKT3 in liver recipients (Harvard-Mass-
achusetts General Hospital. 1986) and a subsequent one by Millis (UCLA. 1988) (83) 
were almost afterthoughts to a long story in which the liver had played a key develop-
mental role. 
In contrast, ASTS received early notification about FKS06. the most recent drug 
to sail through the FDA, this time with wings mounted almost exclusively on the liver. 
The lag between the first published report in The Lancet of this drug's clinical use 
(October 1989) and presentations at the European Society of Organ Transplantation 
(October 1989), American Surgical Association (April 1990), ASTS (May 1990) (84), 
and Transplantation Society (August 1990, San Francisco) was numbered in days to 
months. At all 3 transplantation meetings, culminating with a prize for the highest 
graded clinical paper at the Transplantation Society, John Fung (Pittsburgh) de-
scribed the rescue with FKS06 of liver recipients with intractable rejection despite 
conventional therapy. Also at the San Francisco meeting,. a profusion of data on satety, 
efficacy, toxicity, pharmacokinetics. and dose. control was documented from an 
already extensive experience with primary transplantation of the liver. kidney, and 
thoracic organs. The subsequent ASTS programs between 1991 and 1993 revealed a 
continuing high interest in this drug. 
Fung returned in 1991 with a report of its favorable: performance in a randomized 
liver trial (85). McMillan (Dallas) was scheduled in 1992 for presentation of a second 
single-center study (86), and in 1993 the results were given separately from the Amer-
ican (Klintmalm) (87) and European randomized trials (Neuhaus. Berlin) (881. Sin-
gle-center toxicity (Stock) and efficacy reports (Esquivel) were given in 1992 and 
1993. respectively, from the 1 San Francisco liver teams (89,90 l. Five months after the 
1993 ASTS meeting. FK506 completed its "fast track" iournev through the FDA with a 
polished tinal protile of efticacv and satetv tor liver transplantation-much the same 
,IS had been presented verballv year bv year to the Transplantation Societv and ASTS. 
Tolerance. The mechanism of this process and means of inducing it with inert antigen 
or live immunocytes have been pursued at ASTS meeting along multiple lines of 
sophisticated in vivo and in vitro inquiry. Liver and intestinal transplantation cast a 
darifving beam on these etforts-rhe liver because it has been long known to be natu-
rallv tolerogenic and the intestine because it is heavilv endowed with the T .md 13 Ivm-
f,hocvces and natural killer cells associated with gratt-versus-host disease (GVHDl. 
Hepatic tolerogenicitv was detined as [he liver·s abilitv to induce its own perma-
nent drug-free acceptance in dogs. aided bv a 4-month postoperative (ourse of aza-
thioprtnt: (Denver. 1':1(5), ~ometlmes without immunosuppression in pIgs I Paris. 
Ilristn/' (ambridge. Jnd Dl!lwer, 1 ':160-1 ':I6i)) and predictablv in sl!verai stram (ombi-
l1atlons or rats I (ambridge. fuk\"O. and Pittsburgh. ILJ75-\ ':IMS) ,InU almost allmousc:: 
'llmbtna[lOnS I Pittsburgh. ILJY_~ 1. ['he auditional demonstration bv t :,dnc t I %':1) ,lilt! 
----- --------------,--------' 
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others at Cambridge that pig and rat liver recipients could freely accept other tissues 
and organs from the same donor created a model for investigation that resisted efforts 
at explanation until recently. In an Upjohn Prize-winning paper in 1988, Yamaguchi 
(with Bollinger. Duke) presented evidence of the central role of Class I MHC antigens 
in hepatic tolerogenicity (91). seemingly congruent with the documentation in Cam-
bridge (discussed by Bruce Roser. invited speaker. 1988) that new circulating soluble 
Class I antigens of donor specificity could be found promptly and permanently in 
human liver recipients (92). 
Although the putatively tolerogenicsoluble antigens werewide1y assumed to be of 
hepatocyte origin. they actually are from the donor nonparenchymal cells (NPCs) 
that are in all tissues and organs ("passenger leukocytes") but are unusually well rep-
resented in the liver. Thus. the persistence of the new soluble Class I antigens was evi-
dence (largely unheeded by investigators) that the NPCs remained viable. In 1992. 
Campos and Naji (University of Pennsylvania) demonstrated in rats that thymic 
injection of donor bone marrow greatly increased natural hepatic tolerogenicity. 
allowing long or permanent Jiver allograft survival in an otherwise strongly rejecting 
strain combination (93). IhterestiligIy. a hepatocyte suspension (which presumably 
contained NPCs) had a similar but much, weaker. effect. 
This special example'ofdonorpClSsengedeukocyte augmentation, with delivery to 
an immunologicallyjmportanttarg~dladbeen'reported 2 years earlier by Naji with 
pancreatic islets. The work generated numerous> derivative studies that included 12 
presented_at -the' 1992 Transpiantation-.5ocietyin- Paris. However •. this was only the tip 
of a previously undetected iceberg tha£'drifted without warning into the postgraduate 
course of the 1992 ASTS meetin.g:.. fll:his invited, lecture on cell. transplantation (94). 
Camillo Ricordi (Pittsburgn) described to an, incredulous. audience the recent invari,.. 
able detection. with sensitive immunocytochemical and molecular (PCR) techniques, 
of ubiquitous donor leukocyte chimerism in human organ recipientS-as long as 3 
decades postoperatively, most prominently in patients with liver allografts. These 
observations-plus the prior knowledge that the NPCs of liver (Colorado. 1969) and 
other allografts (Pittsburgh 1991-1992) are replaced by recipient cells of the same lin-
c!ages-implied a bidirectional migration of immunocvtes after transplantation. The 
dynamics were promptly worked out by Demetris. Murase. and Qian (Pittsburgh), 
nrst in rats and then in mice ( 1991-1993) after intestinal and liver transplantation. 
Clinical success was detined as the bodv-wide David and Goliath engagement of 
the cells of the donor mini-immune system (the passenger lcukol:vte component of 
the allograft) with those of the recipient immune system. and an immunologic truce 
reached by these mixed leukocytes was postulated to detine dinical success. The 
inability to achieve such a resolution was tantamount to clinical failure. detined most 
(ommonly by the timiiiar host-yersus-graft reaction (rejection l. but less commonly 
by an imbalance in the other direction leading to GVHD (which. in the past. has not 
been commonly recognizedl. Both HVG .lnd GVHD reactions may ()(cur simultane-
ously. In addition to the inherent immune reactivity of the host immune system. the 
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constituency of the organ transplanted. Both of these quantitative and qualitative fac-
tors of the NPCs are especially favorable with the liver. 
In this new paradigm, the appearance of suppressor cells, veto cells, cytokines. 
and other immunobiologic changes that had long dominated ASTS programs were 
seen as epiphenomena --secondary to the seminal event of cell migration and 
microchimerism. In nonrejecting chimeric mouse liver recipients never exposed to 
immunosuppression. Dahmen (Pittsburgh. 1993) (95) demonstrated "split toler-
ance" after one month or much longer. This was defined by these animals' acceptance 
of donor strain hearts or skin (but not third-party allografts) at the same time as in 
vitro antidonor activity measurable with MLR and CML.An implication of these 
clinical and experimental discoveries was that many long-surviving human liver 
recipients were being maintained on protocol immunosuppression that was no longer 
necessary. This was strongly supported at the 1993 ASTS meeting by Reyes' report of 
23 liver recipients whose treatment had been stopped 6 months to 20 years posttrans-
plant, with subsequent rejection-free intervals of 1 to 18 years (96). 
Because the chimeric leukocytes dispersed from the allograft are of bone marrow 
origin, a therapeutic corollary was that acceptance of less favored organs' such as the 
heart and kidney (or even the liver itself) could be facilitated by the infusion ofunal .. 
tered donor bone marrow perioperatively. D()DorleukoCyteinfllsion.to.induc:etoler-
ance was the most ancient therapeutic strategy of transplantation immunology but 
perhaps the least well understood. It wastirst used.by prehnand.Main.(NIH, 1955) 
and Trentin (Houston. 1956). who showed that lethally irradiated adult micerecon-
stituted with allogeneic bone marrow could accept skin from the' same donor strain 
but no other. These were efforts to mimic the 2 conditions (inoculation of mature 
donor immunocytes and immunologic non reactivity of recipients ) which had 
allowed Billingham. Brent. and Medawar (1953) to induce acquired tolerance of 
neonatailv or perinatally iniected mice. Thousands of similar experiments. as well as 
the treatment poliCY in the clinical tield of bone marrow transplantation. have 
,lssumed the need for either a natural or an imposed state of host nonreactivitv. The 
~onsequent risk ofGVHD was described by Billingham and Brent 111J56). The dimen-
sions of the GVHD problem proved to be so great ciinicaily that a dozen years passed 
before Robert Good ( 1968. ~linnesota) and Donnall Thomas ( 1969. Seattle) were able 
to report the tirst successful examples of human bone marrow transplantation. and 
then onlv with perfect donor-recipient HLA matching. 
(n attempts to induce tolerance to whole organs while avoiding the GVHD trap. 
t ;ood. Kdlv. Lillehei. and their assocIates gave leukocyte membranes prepared trom 
donor whitel:dl pack to renal transplant recipients preoperatively. This was a pream-
hie to the widespread current practice of pretransplant donor-specitic blood transtu-
'Ion n:ported by Salvatierra (American Surgical Association. 19XO: ASTS. 19H5) (~71. 
:--'Ionaco reported at the [':l75 ASTS meeting (':IH) that he had ~iYt!n G\'opre!it!rYed 
Il1!ra\,enUU:i Jonor bone marrow to a patient 25 Jays after cadaver kidney t ransplanta-
{IOn. with ~l ~uud clinical re!iulc. until death 8 months latt:r from a wloni!.: perforation. 
rhe treatment sl:hedule til inJul:tlun Immunosuppression with :\LS (IIr ;\LG) plu!i 
(onventlollal agents. With Jdaved Intu~iull ot bont! marrow. hJS bc:en (ailed the 
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"Monaco model," developed systematically by Monaco, Wood, and Russell in mice 
( 1966) and in dogs ( 1973), and then by Thomas (1985) in subhuman primates. More 
than 10 years passed before marrow augmentation was tried again in trials of cadaver 
renal transplantation in Alabama. presented by Barber at the 1988 (99) and the 1990 
(100) ASTS meetings. The cliniCal results were promising but inconclusive. possibly 
because of uncertainty about cell viability and because of the timing in the protocols. 
In some of these historically important initiatives. the cells were deh"berately 
killed. In others. it was assumed they had a short life span in the recipient environ-
ment. It may be suggested now that, in the Minnesota and California trials. the aug-
menting antigen or leukocytes were given too early--causing sensitization of some of 
their patients. In the Alabama trials (based on the Monaco model), they may have 
been given too late (20 days after renal transplantation) for optimal effect. Armed 
with the discoveries that natural chimerism from the graft itself begins within minutes 
of organ revascularization and persists, it was possible during 1993 to simulate this 
timing in unconditioned patients whose transplanted organ, immunosuppression, 
and adjuvant bone marrow allarrivedpedoperatively; At the 1993 ASTS postgIaduate 
session (·101) the uncomplicated courses were describeclofthe tirst dozen kidney and 
liver recipients who hadbeengivendx108 unaltered.bone marrow cells/kgintraoper-
atively and then were treated.:with routine FK506-prednisone immunosuppression. 
All recipients had 0.8% to. 15%. circulating donor leukocytes 1 to 8 months later, and 
all had good function of their whole organaHografts. None developed GVHD, which 
was consistent with earlier observation. in rodentsby Slavin and Strober ( 1977) and by 
Ildstad and Sachs ( 1984) onthesatetyofmixed chimerism. 
Such cell augmentation forintestinaLtransplantation would have been inconceiv-
able with the previous understanding of transplantation immunology. However,the' 
freedom from GVHD of human intestinal recipients reported by Todo and Tzakis 
(74.75) could now be explained by the canceling interactions of the coexisting cell 
populations. L~'mphoid depletion of the graft. as suggested by the research of the Har-
vard-Northeastern group (77-801. appeared to be unnecessarv.ln fact. it was probably 
contraindicated because it was associated in earlier cases with a high incidence of B 
LeU lymphomas. However. T ,ell depletion of the infused cells mav be needed if the 
bone marrow is to be used safely in potentially <.NHD-prone intestinal recipients. 
The same questions about immunologic balancc must be addressed in strategies 
to induce the acceptance of organ xcnografts. These organs have been shown in ani-
mals and humans l Pittsburgh. 1992) (571 to generate bidirectional migration patterns 
~imilar [() allografts. if they survive antibody and complement activ;uion whose effect 
is to devascularize the organ bv occluding its microvasculature. As discussed by Rieor-
..Ii. the individual tree cells ofaxenograft have less jeopardv than the whole organ. 
HLA MatcJlin~. During the last 5 vcars. groups from C.lInbrid~e and Pittsburgh have: 
n:porteJ .111 Inverse Lorrelation between HL\ Illa(chin~ ,lila dinical livcr tr::msplant 
resulls, !"ht!se reports have added to questions about the C:1lI~matlL ll1abilitv of HL\ 
tcchnolol!v to Jccuratelv predict thc olltcome wllh ,IIlV organ. rhe I,lew paradigm 01 
::rart aLL~pt;1I1ce ltnplics a postoper:ltIw dwindlin~ of.1I1 :-'1 He cltect ~}l'glDning short-
----------------------------------
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ly after the transplantation of all organs, an effect that is proportional to the load of 
donor migratory cells introduced by the specific kind of allograft. This explanation is 
compatible with the mouse liver transplant experiments of Dahmen and Qian (95), in 
which the effect of MHC Class I, II. and minor incompatibility was diminished or 
lost. even without immunosuppression. 
Discussion 
It is tempting in reviewing our meetings to indulge in mutual congratulations. but 
this would militate against course correction if indicated. Scientific and clinical spe-
cialties develop a formidable collective wisdom that safeguards their integrity and 
prevents the irresponsible dissemination of false information. However. the resulting 
conservatism can itself impede progress. perpetuate dogma. and inhibit creative 
movement. With 19 years of annual ASTS programs before us, we can objectively 
assess the extent to which we have avoided such self-entrapment by asking 4 ques-
tions: ( 1) Did the selected abstracts and invited lectures announce major advances in 
the tleld? (2) Were the ideas valid in retrospect? (3)· Did they germinate further devel-
opments? and (4) Were manuscripts provided by the authors and, if so. what became 
of them? 
By these criteria. ASTS cannot receive an "honors" grade for liver and intestinal 
transplantation. in part because so many of the presentations were late reflections of 
earlier work. Whether this was due to failure to submit abstracts or to their culling. by 
program committees is not possible to determine. Such concern about program 
development is inevitable in all societies that conductpopular congresses. but perhaps 
more frequently expressed in ours because of the vastintellectual range of interest of 
its membership. However. at either side of the resulting gap. we should find ways to air 
uncontirmed scientitic observations. innovations. new drug initiatives. and manage-
ment strategies that have not yet met format-restricted standards (which are more 
attuned to verification and detail than to original discoverv), 
[n addition. it must be noted for the benetit of future archivists how tilr the wrt(-
t~n record of our meetmgs has taUen short of the real wntent. LX the ':6 presentations 
on the liver and intestine given between 11j77 .md 11j1j3. onlv 0 I (04% 1 appeared in or 
have been accepted for our designated outlet. the iournal Trcmspiallttltioll (see bibliog-
raphy), Failure to achieve this tinal step is rare at the international Transplantation 
Socict\' congresses. and almost unheard-of in some of the most distinguished and plu-
ralistic protessional organizations. such as the American Surgical Association (which 
,elects onlv 35 abstracts from more than -tOO. but then publishes them all in the 
:\mwis vtSurger)' J. ,-\STS (and probablv also ASTPl should ~xplore arran~cments th~H 
will allow the membership to review its own proceedings In an orderlv wav ex post 
1,lctoo This (ould be accomplished with a supplcmental issuc L"onrainin~ cxtended 
,1bstrJLts, kaving the option open or' full manuscript submission to [nlt/srlt/1HiltlO/1 
,lnd other journals tllr thcir normal avenucs ol recr rcviewo 
With thc disL"Jnicd papers Oil the [iver and inrcstlnc, lh~ Iloor diSCUSSions of the 
lerhal ~)rCscntatlOns Jiso havc hccn lost to f'ostert(\', [Ohis willltlin~ .IW.IV of pro~r.lm 
._--------_._. __ ........ _ .._----_ .... _---------
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substance could have been due to an unsa.tisfactory caliber of manuscripts, the failure 
to submit them, or an unrealistically critical editorial process reflecting a different 
purpose than that of the selection and program committees. Any of these factors, if 
uncorrected, will ultimately weaken our society by undermining its main purpose of 
unfettered communication. 
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